









Markets
/
Stocks
/
nasdaq-lptx
/

Leap Therapeutics Inc

LPTX

0.290USD

-0.032-9.83%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

12.01MMarket Cap

LossP/E TTM



Leap Therapeutics Inc

0.290

-0.032-9.83%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

232 / 506

Overall Ranking

375 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Hold

Current Rating

3.000

Target Price

+669.23%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 24.16.

Overvalued

The company’s latest PE is -0.18, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 18.70M shares, decreasing 31.39% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.16M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.51.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.81, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.81

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.48

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.81

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -0.20, which is 88.71% below the recent high of -0.39 and -604.55% above the recent low of -1.44.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 232/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 6.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Leap Therapeutics Inc is 3.00, with a high of 3.00 and a low of 3.00.

Score

Industry at a Glance

Previous score

6.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Hold

Current Rating

3.000

Target Price

+669.23%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Leap Therapeutics Inc

LPTX

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 2.73, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 0.34 and the support level at 0.28, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

2.73

Change

-0.36

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.007

Neutral

RSI(14)

46.183

Neutral

STOCH(KDJ)(9,3,3)

61.704

Sell

ATR(14)

0.022

High Vlolatility

CCI(14)

15.232

Neutral

Williams %R

63.978

Sell

TRIX(12,20)

-0.019

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.310

Sell

MA10

0.299

Sell

MA20

0.296

Sell

MA50

0.312

Sell

MA100

0.338

Sell

MA200

0.847

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 45.12%, representing a quarter-over-quarter decrease of 1.09%. The largest institutional shareholder is The Vanguard, holding a total of 1.16M shares, representing 2.80% of shares outstanding, with 9.86% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Gilead Sciences Inc

5.32M

683 Capital Management LLC

1.45M

+7.40%

Acadian Asset Management LLC

1.28M

+470.43%

Beigene Ltd

1.22M

The Vanguard Group, Inc.

Star Investors

1.18M

-1.29%

Monaco asset management S.A.M.

1.05M

+410.02%

Simplify Asset Management Inc

950.97K

+0.52%

HealthCare Ventures LLC

697.23K

+3.09%

Key Client Fiduciary Advisors, LLC

388.72K

+7.60%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.94, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is -0.16. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.